medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2021, Number 4

<< Back Next >>

Medicina & Laboratorio 2021; 25 (4)

HIV-related lymphomas: a complex and frequent association. A narrative review of the literature

Herrera-Rueda GA, Mogollón-Vargas JM, Serrano-García AY, Gaviria-Jaramillo LM

Language: Spanish
References: 39
Page: 695-707
PDF size: 116.58 Kb.


ABSTRACT

In Colombia, human immunodeficiency virus (HIV) infection is a growing epidemic. Given the improvement in overall survival with highly effective antiretroviral therapy, cancer has been displacing infectious complications in this population. Non-Hodgkin's lymphoma is the most common AIDS defining malignancy after Kaposi's sarcoma. Diffuse large B-cell lymphoma and Burkitt’s lymphoma are the most common variants; meanwhile, the risk of developing classical Hodgkin lymphoma is 5 to 20-fold higher compared to HIV-negative individuals. Making an early diagnosis is a challenge, due to opportunistic infections and the atypical presentation of the disease in this group of patients. Treatment of the disease is also a challenge given the comorbidities and patient condition at diagnosis; however, in conjunction with combined chemotherapy regimens and the concomitant use of antiretroviral therapy, the outcome of patients with AIDS-related lymphomas has significantly improved, currently approaching that of seronegative patients. The aim of this review article is to describe the main characteristics of the disease, in such a way that it allows health workers to have more elements for a comprehensive approach in patients with AIDS-related lymphomas in our country.


REFERENCES

  1. United Nations. UNAIDS: Joint United NationsProgramme on HIV/AIDS. New York, EstadosUnidos: United Nations; 2015. Acceso 16 de juliode 2021. Disponible en https://www.un.org/youthenvoy/2013/08/unaids-joint-united-nations-programme-on-hivaids/.

  2. Yarchoan R, Uldrick TS. HIV-associated cancersand related diseases. N Engl J Med2018;378:1029-1041. https://doi.org/10.1056/NEJMra1615896.

  3. Noy A. HIV and lymphoma: from oncologicalfutility to treatment. LancetHIV 2020;7:e598-e600. https://doi.org/10.1016/s2352-3018(20)30227-7.

  4. Morlat P, Roussillon C, Henard S, Salmon D,Bonnet F, Cacoub P, et al. Causes of deathamong HIV-infected patients in France in 2010(national survey): trends since 2000. Aids2014;28:1181-1191. https://doi.org/10.1097/qad.0000000000000222.

  5. Kimani SM, Painschab MS, Horner MJ,Muchengeti M, Fedoriw Y, Shiels MS, etal. Epidemiology of haematological malignanciesin people living with HIV. Lancet HIV2020;7:e641-e651. https://doi.org/10.1016/s2352-3018(20)30118-1.

  6. Montana JF, Ferreira G, Cunha CLF, de QueirozAAR, Fernandes WAA, Polaro SHI, et al.The HIV epidemic in Colombia: spatial andtemporal trends analysis. BMC Public Health2021;21:178. https://doi.org/10.1186/s12889-021-10196-y.

  7. Fink VI, Shepherd BE, Cesar C, KrolewieckiA, Wehbe F, Cortés CP, et al. Cancer in HIVinfectedpersons from the Caribbean, Centraland South America. J Acquir Immune Defic Syndr2011;56:467-473. https://doi.org/10.1097/qai.0b013e31820bb1c3.

  8. AIDS-defining Cancer Project Working Groupof IeDEA, COHERE in EuroCoord. Non-Hodgkinlymphoma risk in adults living with HIV acrossfive continents. Aids 2018;32:2777-2786. https://doi.org/10.1097/qad.0000000000002003.

  9. Álvarez-Guevara D, Cuervo-Maldonado S,Sánchez R, Gómez-Rincón J, Ramírez N.Prevalence of defining malignancies in adultpatients with HIV/AIDS in the National CancerInstitute of Colombia. 2007-2014. Rev Fac Med2017;65:397-402.

  10. Uribe-Parra D, Pulido D, Lopes G, Martinez P,Acuña L, Valencia O, et al. Cancer incidence inpatients diagnosed with acquired immunodeficiencysyndrome (AIDS) in Colombia. J AIDSClin Res 2017;08. https://doi.org/10.4172/2155-6113.1000692.

  11. Carbone A, Vaccher E, Gloghini A, PantanowitzL, Abayomi A, de Paoli P, et al. Diagnosisand management of lymphomas andother cancers in HIV-infected patients. NatRev Clin Oncol 2014;11:223-238. https://doi.org/10.1038/nrclinonc.2014.31.

  12. Candeias SM, Gaipl US. The immune system incancer prevention, development and therapy.Anticancer Agents Med Chem 2016;16:101-107. https://doi.org/10.2174/1871520615666150824153523.

  13. Silverberg MJ, Chao C, Leyden WA, Xu L, TangB, Horberg MA, et al. HIV infection and the riskof cancers with and without a known infectiouscause. Aids 2009;23:2337-2345. https://doi.org/10.1097/QAD.0b013e3283319184.

  14. Wiggill TM, Mantina H, Willem P, Perner Y,Stevens WS. Changing pattern of lymphomasubgroups at a tertiary academic complex ina high-prevalence HIV setting: a South Africanperspective. J Acquir Immune Defic Syndr2011;56:460-466. https://doi.org/10.1097/QAI.0b013e31820bb06a.

  15. Martorelli D, Muraro E, Mastorci K, Dal Col J,Faè DA, Furlan C, et al. A natural HIV p17 proteinvariant up-regulates the LMP-1 EBV oncoproteinand promotes the growth of EBV-infectedB-lymphocytes: implications for EBV-driven lymphomagenesisin the HIV setting. Int J Cancer2015;137:1374-1385. https://doi.org/10.1002/ijc.29494.

  16. Pantanowitz L, Carbone A, Dolcetti R. Microenvironmentand HIV-related lymphomagenesis.Semin Cancer Biol 2015;34:52-57. https://doi.org/10.1016/j.semcancer.2015.06.002.

  17. Zhang J, Grubor V, Love CL, Banerjee A,Richards KL, Miezcowski P, et al. The geneticlandscape of immune-competent and HIVlymphoma. Infect Agent Cancer 2012;7:O1.https://doi.org/10.1186/1750-9378-7-S1-O1.

  18. Castelli AA, Rosenthal DG, Bender Ignacio R,Chu HY. Hemophagocytic lymphohistiocytosissecondary to human immunodeficiency virusassociatedhistoplasmosis. Open Forum InfectDis 2015;2:ofv140. https://doi.org/10.1093/ofid/ofv140.

  19. Reddy D, Mitsuyasu R. HIV-associated multicentricCastleman disease. Curr Opin Oncol

  20. 2011;23:475-481. https://doi.org/10.1097/CCO.0b013e328349c233.20. Antel K, Levetan C, Mohamed Z, Louw VJ,Oosthuizen J, Maartens G, et al. The determinantsand impact of diagnostic delay in lymphomain a TB and HIV endemic setting. BMCCancer 2019;19:384. https://doi.org/10.1186/s12885-019-5586-4.

  21. Cortez MV, Oliveira CM, Monte RL, Araújo JR,Braga BB, Reis DZ, et al. HIV-associated tuberculouslymphadenitis: the importance of polymerasechain reaction (PCR) as a complementary tool forthe diagnosis of tuberculosis - a study of 104 patients.An Bras Dermatol 2011;86:925-931. https://doi.org/10.1590/s0365-05962011000500010.

  22. Shao L, Jiang L, Wu S, Yu L, Wang L, HuangX. Simultaneous occurrence of invasive pulmonaryaspergillosis and diffuse large B-cell lymphoma:case report and literature review. BMCCancer 2020;20:15. https://doi.org/10.1186/s12885-019-6471-x.

  23. Kaplan LD. HIV-associated lymphoma. BestPract Res Clin Haematol 2012;25:101-117.https://doi.org/10.1016/j.beha.2012.01.001.

  24. Brunnberg U, Hentrich M, Hoffmann C, WolfT, Hübel K. HIV-associated malignant lymphoma.Oncol Res Treat 2017;40:82-87. https://doi.org/10.1159/000456036.

  25. International Agency for Research on Cancer(IARC). WHO Classification of Tumours ofHaematopoietic and Lymphoid Tissues. 4th eded. Lyon: International Agency for Research onCancer (IARC); 2017. p. 581

  26. Barta SK, Xue X, Wang D, Tamari R, Lee JY,Mounier N, et al. Treatment factors affectingoutcomes in HIV-associated non-Hodgkinlymphomas: a pooled analysis of 1546 patients.Blood 2013;122:3251-3262. https://doi.org/10.1182/blood-2013-04-498964.

  27. Calkins KL, Chander G, Joshu CE, VisvanathanK, Fojo AT, Lesko CR, et al. Immunestatus and associated mortality after cancertreatment among individuals with HIV inthe antiretroviral therapy era. JAMA Oncol2020;6:227-235. https://doi.org/10.1001/jamaoncol.2019.4648.

  28. Sparano JA, Lee JY, Kaplan LD, LevineAM, Ramos JC, Ambinder RF, et al. Rituximabplus concurrent infusional EPOCH chemotherapyis highly effective in HIV-associatedB-cell non-Hodgkin lymphoma. Blood2010;115:3008-3016. https://doi.org/10.1182/blood-2009-08-231613.

  29. Barta SK, Lee JY, Kaplan LD, Noy A, SparanoJA. Pooled analysis of AIDS malignancy consortiumtrials evaluating rituximab plus CHOP or infusionalEPOCH chemotherapy in HIV-associatednon-Hodgkin lymphoma. Cancer 2012;118:3977-3983. https://doi.org/10.1002/cncr.26723.

  30. Hegde U, Filie A, Little RF, Janik JE, Grant N,Steinberg SM, et al. High incidence of occultleptomeningeal disease detected by flow cytometryin newly diagnosed aggressive B-celllymphomas at risk for central nervous systeminvolvement: the role of flow cytometry versuscytology. Blood 2005;105:496-502. https://doi.org/10.1182/blood-2004-05-1982.

  31. National Comprehensive Cancer Network(NCCN). NCCN Guidelines. B-cell lymphomas.Pensilvania, Estados Unidos: NationalComprehensive Cancer Network; 2021. Acceso05 de mayo de 2021. Disponible enhttps://www.nccn.org/guidelines/guidelinesdetail?category=1&id=1480.

  32. Rubinstein PG, Moore PC, Rudek MA, HenryDH, Ramos JC, Ratner L, et al. Brentuximabvedotin with AVD shows safety, in the absenceof strong CYP3A4 inhibitors, in newly diagnosedHIV-associated Hodgkin lymphoma. Aids2018;32:605-611. https://doi.org/10.1097/qad.0000000000001729.

  33. Castillo JJ, Reagan JL, Sikov WM, WinerES. Bortezomib in combination with infusionaldose-adjusted EPOCH for the treatmentof plasmablastic lymphoma. Br J Haematol2015;169:352-355. https://doi.org/10.1111/bjh.13300.

  34. Alvarnas JC, Le Rademacher J, Wang Y, LittleRF, Akpek G, Ayala E, et al. Autologous hematopoieticcell transplantation for HIV-relatedlymphoma: results of the BMT CTN 0803/AMC071 trial. Blood 2016;128:1050-1058. https://doi.org/10.1182/blood-2015-08-664706.

  35. Hütter G, Nowak D, Mossner M, Ganepola S,Müssig A, Allers K, et al. Long-term control ofHIV by CCR5 Delta32/Delta32 stem-cell transplantation.N Engl J Med 2009;360:692-698.https://doi.org/10.1056/NEJMoa0802905.

  36. Meister A, Hentrich M, Wyen C, Hübel K. Malignantlymphoma in the HIV-positive patient.Eur J Haematol 2018;101:119-126. https://doi.org/10.1111/ejh.13082.

  37. Wu D, Chen C, Zhang M, Li Z, Wang S, ShiJ, et al. The clinical features and prognosisof 100 AIDS-related lymphoma cases. SciRep 2019;9:5381. https://doi.org/10.1038/s41598-019-41869-9.

  38. Noy A. Optimizing treatment of HIV-associatedlymphoma. Blood 2019;134:1385-1394. https://doi.org/10.1182/blood-2018-01-791400.

  39. Jacobson CA, Abramson JS. HIV-associatedHodgkin's lymphoma: Prognosis and therapy inthe era of cART. Adv Hematol 2012;2012:507257.https://doi.org/10.1155/2012/507257.




2020     |     www.medigraphic.com